Editor’s Note: This article originally appeared on the American Medical Association’s website.
Signed into law this week, Arkansas Act 964 requires all health insurers and the Arkansas Medicaid program to remove prior authorization to FDA-approved medications that have been shown to support recovery, reduce health care costs and save lives, including buprenorphine, methadone and naltrexone. These medications are part of what is commonly referred to as medication-assisted treatment (MAT), considered the gold standard for treating OUD, according to the U.S. Surgeon General. Click here to continue>>
News from our partners.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
